Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease
Cardio Diagnostics Holdings Inc. (
NASDAQ: CDIO), a precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease (CHD). Specifically, AGEPHA Pharma will supply LODOCO® (low-dose colchicine), its FDA-approved anti-inflammatory medication, for a Cardio Diagnostics-sponsored clinical study to explore the use of Cardio Diagnostics’ PrecisionCHD™ blood test to identify patients with inflammation-driven coronary heart disease (CHD) and assess their response to LODOCO® over time.
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio. The patent, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,” (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics’ founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors.
